Stockscreener 앱 받기
2.28
0.00%
0.00
시간 외 거래:
2.31
0.03
+1.32%
전일 마감가:
$2.28
열려 있는:
$2.27
하루 거래량:
30,001
Relative Volume:
0.14
시가총액:
$5.72M
수익:
$960.60K
순이익/손실:
$-7.10M
주가수익비율:
-0.3016
EPS:
-7.56
순현금흐름:
$-8.00M
1주 성능:
-5.55%
1개월 성능:
-27.16%
6개월 성능:
-42.57%
1년 성능:
-78.38%
1일 변동 폭
$2.16
$2.35
1주일 범위
$2.16
$2.51
52주 변동 폭
$1.8301
$14.92
Soligenix Inc Stock (SNGX) Company Profile
명칭
Soligenix Inc
전화
609-538-8200
주소
29 EMMONS DRIVE, PRINCETON
SNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
2.28 | 5.72M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-28 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2018-01-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 재확인 | Maxim Group | Buy |
| 2017-07-17 | 개시 | H.C. Wainwright | Buy |
Soligenix Inc 주식(SNGX)의 최신 뉴스
Soligenix on Way to Bio Conference in NYC - Baystreet.ca
Rare Disease Pioneer Soligenix Takes Center Stage at Major Biotech Investor Summit - StockTitan
Symbol Lookup - GuruFocus.com
Soligenix (NASDAQ:SNGX) & Rhythm Pharmaceuticals (NASDAQ:RYTM) Head to Head Contrast - Defense World
Soligenix (SNGX) Stock Price, News & Analysis - MarketBeat
Soligenix (NASDAQ: $SNGX) Unveils Two-Pronged Approach To Tackle Rare Diseases & Unmet Medical Needs - MSN
Soligenix to Present at Upcoming Investor Conferences - PR Newswire
Soligenix to Present at Two Major Investor Conferences in January 2024 - StockTitan
Stock market today: Phio Pharmaceuticals -20.76%, Soligenix -20.15% among biggest losers in early trading - Business Upturn
SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL… - MSN
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year - AOL
SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL - Smartkarma
Soligenix's HyBryte Shows 70% Success Rate in CTCL Treatment Study, Complete Response in Some Patients - StockTitan
Cutaneous T-cell Lymphoma Market on Track for Major Expansion - openPR
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - StockTitan
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte - Citybuzz
Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial - Yahoo Finance
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL - Nasdaq
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway - Smartkarma
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer - AOL
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… - Zacks Small Cap Research
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing - AccessWire
Soligenix's HyBryte™ Shows 3x Better Response Rate vs Valchlor® in Rare Disease Trial - StockTitan
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - The Malaysian Reserve
Soligenix (STU:DOA) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs - Nasdaq
Soligenix Advances Promising Treatments for Rare Diseases and Public Health Threats - Citybuzz
Soligenix Announces Recent Accomplishments And Third Quarter 202 - GuruFocus.com
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusqueti - GuruFocus.com
Soligenix Launches European Advisory Board for Phase 3 HyBryte CTCL Trial - Dermatology Times
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire
Soligenix Trumpets Q2 Numbers - MENAFN.COM
Soligenix to Present at Q4 Investor Summit: Rare Disease Treatment Pipeline in Focus | SNGX Stock News - StockTitan
Brokers Offer Predictions for Soligenix FY2024 Earnings - Defense World
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - The Malaysian Reserve
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels - AOL
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 for the Treatment of Behcet's Disease - Marketscreener.com
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024 - MSN
Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) - Yahoo Finance
Soligenix Inc. (SNGX) Quarterly 10-Q Report - Quartz
SEC Form 424B3 filed by Soligenix Inc. - Quantisnow
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - citybiz
Soligenix Reports Q3 Loss, Advances Clinical Pipeline with $9.8M Cash Position | SNGX Stock News - StockTitan
Soligenix Granted FDA Orphan Drug Designation For SuVax Active Ingredient - Contract Pharma
Oral Mucositis Market Forecasted to Surge in Coming Years, - openPR
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference - GlobeNewswire
Soligenix Inc (SNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.02%
0.32%
자본화:
|
볼륨(24시간):